The National Quality Forum (NQF) currently serves as the consensus-based quality-measure-endorsement entity called for in the Affordable Care Act. Measures are submitted to the NQF by professional societies, government agencies, health systems, nonprofit organizations, and industry. Multistakeholder expert committees assess proposed measures using specific evaluation criteria. Endorsed measures are often adopted by the Centers for Medicare & Medicaid Services in payment and public reporting programs. 3 We determined how NQF-endorsed process measures match the entire IOM framework and concentrated on quality measures that evaluate the prediagnostic care of patients presenting with signs or symptoms. We then compared these sign/symptom-based quality measures with the most common reasons people seek care.
Methods | Based on predefined criteria (eAppendix in the Supplement), 3 of the authors categorized each NQFendorsed process measure into 1 of the 5 IOM groups. We then subclassified the evaluation/diagnosis-and managementrelated measures by their NQF-designated denominator and numerator. The NQF denominator indicates the characteristic or population to which the quality measure applies. We grouped denominator statements by sign/symptom (eg, chest pain), established diagnosis (eg, diabetes), procedure (eg, coronary artery bypass grafting), medication (eg, lithium), diagnostic test (eg, carotid imaging study), or other. The numeraSupplemental content at jama.com Percentage of patients aged 18 y or older who are screened for unhealthy alcohol use at least once during the 2-year measurement period using a systematic screening method and who will receive brief counseling (numerator) if identified as an unhealthy alcohol user (denominator)
a Includes blood, urine, and pathology tests.
b All numerators not pertaining to in vitro diagnostics and medical imaging were considered other. The majority of these included treatments (eg, medication, counseling, and rehabilitation) or medical record documentation.
tor is the action taken by a clinician. We grouped numerator statements into use of in vitro diagnostics (IVD), which include blood, urine, and pathology tests; medical imaging; or other, which most often described a treatment ( Table 1) . We used 2010 National (Hospital) Ambulatory Medical Care Survey data to compare the sign/symptom-based measures with the most common reasons people seek care.
4,5
Results | Of 372 process quality measures listed on the NQF website as of June 4, 2014, 360 were coded into a unique IOM category, 11 into 2 categories, and 1 into 3 categories, resulting in 385 codings. Approximately two-thirds (n = 267) targeted disease management and 12% (n = 46) targeted evaluation/ diagnosis. The remaining were evenly distributed among prevention, screening, and follow-up. Of 313 measures pertaining to evaluation/diagnosis or management, 211 (67%) began with an established diagnosis, whereas 14 (4.5%) started with a sign/symptom. The sign/symptom-based measures focused on geriatric care (eg, memory loss, falls, urine leakage) or emergency department care (eg, chest pain). In contrast, many common reasons for which patients seek care, including fever, cough, headache, shortness of breath, earache, rash, and throat symptoms, were not reflected by the quality measures ( Table 2) .
4,5 The performance of an IVD or medical imaging study was the action required by 59 of 313 (19%) endorsed quality measures; many others required actions related to medication prescribing.
Discussion | Existing NQF-endorsed process measures focus predominantly on management of patients with established diagnoses. The prediagnostic care of patients is rarely assessed, and the 14 sign/symptom-based measures infrequently reflect the most common reasons patients seek care. Even though we used defined coding criteria, our work is limited by subjective categorization of the measures and our Younger patients with a bioprosthetic valve have a higher rate of structural valve deterioration than older patients; in 1 study 4 with more than 10 years of follow-up, structural valve deterioration was 6% in patients aged 61 to 70 years and 18% in those aged 51 to 60 years. As a result, the hazard ratio for death after implantation of mechanical vs bioprosthetic valves can vary significantly in different age categories, with the highest mortality benefit using a mechanical valve in younger patients. 5 Therefore, the authors should perform a subgroup analysis according to age tertiles to ensure that their findings are consistent across age groups. In the study by Chiang et al, 1 patients with a bioprosthesis required higher rates of reoperation, whereas the rate of major bleeding was higher with mechanical valves. However, major bleeding included relatively minor events of hematuria and hemoptysis, as well as more severe events of intracranial hemorrhage, cardiac tamponade, and gastrointestinal hemorrhage. Without further data on the severity of bleeding (number of packed red blood cell transfusions, length of hospitalization, and decrease in hemoglobin level), the effect of bleeding on quality of life remains unclear. In contrast to bleeding events that have a short-term effect on quality of life, the problem of structural valve deterioration is a gradual process affecting quality of life over a longer period. Moreover, multiple reoperations may be required as life expectancy increases, which can be associated with additional risks of complications and reduced quality of life. Lowering the age cutoff to implant bioprosthetic valves therefore seems counterintuitive. For these reasons, randomized trials need to be performed to allow estimation of an individual patient's riskbenefit ratio based on mortality, reoperation, bleeding, and quality of life. Until then, we do not believe the available evidence supports lowering the age cutoff for bioprosthetic valves.
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